Construction and analysis of sample-specific driver modules for breast cancer

Background It is important to understand the functional impact of somatic mutation and methylation aberration at an individual level to implement precision medicine. Recent studies have demonstrated that the perturbation of gene interaction networks can provide a fundamental link between genotype (or epigenotype) and phenotype. However, it is unclear how individual mutations affect the function of biological networks, especially for individual methylation aberration. To solve this, we provided a sample-specific driver module construction method using the 2-order network theory and hub-gene theory to identify individual perturbation networks driven by mutations or methylation aberrations. Results Our method integrated multi-omics of breast cancer, including genomics, transcriptomics, epigenomics and interactomics, and provided new insight into the synergistic collaboration between methylation and mutation at an individual level. A common driver pattern of breast cancer was identified from a novel perspective of a driver module, which is correlated to the occurrence and development of breast cancer. The constructed driver module reflects the survival prognosis and degree of malignancy among different subtypes of breast cancer. Additionally, subtype-specific driver modules were identified. Conclusions This study explores the driver module of individual cancer, and contributes to a better understanding of the mechanism of breast cancer driven by the mutations and methylation variations from the point of view of the driver network. This work will help identify new therapeutic combinations of gene mutations and drugs in humans.

Automated summary

This study utilized the 2-order network theory and hub-gene theory to construct sample-specific driver modules, identifying individual perturbation networks driven by mutations or methylation aberrations. The research revealed common driver patterns and subtype-specific driver modules in breast cancer, reflecting survival prognosis and malignancy degree. The findings contribute to a better understanding of breast cancer mechanisms driven by mutations and methylation variations, potentially leading to new therapeutic combinations.